Current and Resolved Drug Shortages and Discontinuations Reported to FDA
Report a Drug Shortage |
Contact Us |
FAQ |
Background Info |
Get Email Alerts |
Download Current Drug Shortages
Start Over | Back to Search Results
Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets
Status: Currently in Shortage
»Date first posted:
10/12/2022
»Therapeutic Categories: Psychiatry
Alvogen (Revised 03/01/2023)
Presentation | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per FDASIA) |
---|---|---|---|
5mg 100 ct (NDC 47781-174-01) | Available | Demand increase | |
10mg 100 ct (NDC 47781-176-01) | Unavailable. Next delivery: mid-March 2023; Estimated recovery: end of March 2023 | Demand increase | |
15mg 100 ct (NDC 47781-178-01) | Unavailable. Next delivery: late March 2023; Estimated recovery: mid-April 2023 | Demand increase | |
20mg 100 ct (NDC 47781-179-01) | Unavailable. Next delivery: Mid-March 2023; Estimated recovery: April 2023 | Demand increase | |
30 mg 100 ct (NDC 47781-180-01) | Unavailable. Next delivery: End-March 2023; Estimated recovery April 2023 | Demand increase |
Aurobindo Pharma USA (New 03/14/2023)
Presentation | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per FDASIA) |
---|---|---|---|
Amphetamine Mixed Salts Tablets C-II 5 mg, 100 (NDC 13107-0068-01) | Estimated availability April 2023 | ||
Amphetamine Mixed Salts Tablets C-II 7.5 mg, 100 (NDC 13107-0069-01) | Estimated availability April 2023 | ||
Amphetamine Mixed Salts Tablets C-II 10 mg, 100 (NDC 13107-0070-01) | Estimated availability April 2023 | ||
Amphetamine Mixed Salts Tablets C-II 15 mg, 100 (NDC 13107-0072-01) | Estimated availability April 2023 | ||
Amphetamine Mixed Salts Tablets C-II 20 mg, 100 (NDC 13107-0073-01) | Estimated availability April 2023 | ||
Amphetamine Mixed Salts Tablets C-II 30 mg, 100 (NDC 13107-0074-01) | Estimated availability April 2023 |
Epic Pharma, LLC (Reverified 03/08/2023)
Presentation | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per FDASIA) |
---|---|---|---|
Amphetamine Salts 20mg C2 100 Tab (NDC 42806-344-01) | Allocation to existing customers only | Shortage of active ingredient | |
Amphetamine Salts10mg C2 100 Tab (NDC 42806-341-01) | Allocation to existing customers only | Shortage of active ingredient | |
Amphetamine Salts 15mg C2 100 Tab (NDC 42806-343-01) | Allocation to existing customers only | Shortage of active ingredient | |
Amphetamine Salts 30mg C2 100 Tab (NDC 42806-345-01) | Allocation to existing customers only | Shortage of active ingredient | |
Amphetamine Salts 5mg C2 100 Tab (NDC 42806-339-01) | Allocation to existing customers only | Shortage of active ingredient |
Lannett Company, Inc. (Reverified 03/10/2023)
Presentation | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per FDASIA) |
---|---|---|---|
5 mg, 100 count (NDC 0527-1500-37) | Available | ||
7.5 mg, 100 count (NDC 0527-1501-37) | Available | ||
10 mg, 100 count (NDC 0527-1502-37) | Available | ||
12.5 mg, 100 count (NDC 0527-1503-37) | Available | ||
15 mg, 100 count (NDC 0527-1504-37) | Available | ||
20 mg, 100 count (NDC 0527-1505-37) | Available | ||
30 mg, 100 count (NDC 0527-1506-37) | Available |
Sandoz (Reverified 03/17/2023)
Presentation | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per FDASIA) |
---|---|---|---|
30 mg, 100 Count Bottle (NDC 0185-2099-01) | Available | ||
20 mg, 100 Count Bottle (NDC 0185-0853-01) | Available | ||
10 mg, 100 Count Bottle (NDC 0185-0842-01) | Available | ||
5 mg, 100 Count Bottle (NDC 0185-2098-01) | Available |
SpecGX LLC (Revised 03/09/2023)
Presentation | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per FDASIA) |
---|---|---|---|
7.5 mg 100 TABLET in 1 BOTTLE (NDC 0406-8884-01) | Backorder until April 2023 | ||
15 mg 100 TABLET in 1 BOTTLE (NDC 0406-8885-01) | Backorder until April 2023 | ||
5 mg 100 TABLET in 1 BOTTLE (NDC 0406-8891-01) | Supply constraints through April 2023 | ||
10 mg 100 TABLET in 1 BOTTLE (NDC 0406-8892-01) | Supply constraints through April 2023 | ||
20 mg 100 TABLET in 1 BOTTLE (NDC 0406-8893-01) | Supply constraints through April 2023 | ||
30 mg 100 TABLET in 1 BOTTLE (NDC 0406-8894-01) | Supply constraints through April 2023 |
Sunrise Pharmaceutical, Inc. (New 10/12/2022)
Presentation | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per FDASIA) |
---|---|---|---|
Amphetamine Mixed Salts Tablets C-II 5 mg, 100 (NDC 11534-190-01) | Available | ||
Amphetamine Mixed Salts Tablets C-II 10 mg, 100 (NDC 11534-192-01) | Available | ||
Amphetamine Mixed Salts Tablets C-II 7.5 mg, 100 (NDC 11534-191-01) | Available | ||
Amphetamine Mixed Salts Tablets C-II 12.5 mg, 100 (NDC 11534-193-01) | Available | ||
Amphetamine Mixed Salts Tablets C-II 15 mg, 100 (NDC 11534-194-01) | Available | ||
Amphetamine Mixed Salts Tablets C-II 20 mg, 100 (NDC 11534-195-01) | Available | ||
Amphetamine Mixed Salts Tablets C-II 30 mg, 100 (NDC 11534-196-01) | Available |
Teva Pharmaceuticals (Revised 03/03/2023)
Presentation | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per FDASIA) |
---|---|---|---|
Adderall(R) Tablets 10mg 100 (NDC 57844-110-01) | Available | Product is available, however Teva continues to experience unprecedented increase in demand. | Demand increase for the drug |
Adderall(R) Tablets 12.5mg 100 (NDC 57844-112-01) | Available | Product is available, however Teva continues to experience unprecedented increase in demand. | Demand increase for the drug |
Adderall(R) Tablets 15mg 100 (NDC 57844-115-01) | Available | Product is available, however Teva continues to experience unprecedented increase in demand. | Demand increase for the drug |
Adderall(R) Tablets 20mg 100 (NDC 57844-120-01) | Available | Product is available, however Teva continues to experience unprecedented increase in demand. | Demand increase for the drug |
Adderall(R) Tablets 30mg 100 (NDC 57844-130-01) | Available | Product is available, however Teva continues to experience unprecedented increase in demand. | Demand increase for the drug |
Adderall(R) Tablets 5mg 100 (NDC 57844-105-01) | Available | Product is available, however Teva continues to experience unprecedented increase in demand. | Demand increase for the drug |
Adderall(R) Tablets 7.5mg 100 (NDC 57844-117-01) | Available | Product is available, however Teva continues to experience unprecedented increase in demand. | Demand increase for the drug |
12.5 mg 100 count (NDC 0555-0776-02) | Product Under Allocation | Unprecedented increase in demand being experienced for the product. Supplying at or above demand currently at low inventory. | Demand increase for the drug |
15 mg 100 count (NDC 0555-0777-02) | Product Under Allocation | Unprecedented increase in demand being experienced for the product. Supplying at or above demand currently at low inventory. | Demand increase for the drug |
7.5 mg 100 count (NDC 0555-0775-02) | Product Under Allocation | Unprecedented increase in demand being experienced for the product. Supplying at or above demand currently at low inventory. | Demand increase for the drug |
10 mg 100 count (NDC 0555-0972-02) | Product Under Allocation | Unprecedented increase in demand being experienced for the product. Supplying at or above demand currently at low inventory. Intermittent supply interruption may be experienced. | Demand increase for the drug |
20 mg 100 count (NDC 0555-0973-02) | Product Under Allocation | Unprecedented increase in demand being experienced for the product. Supplying at or above demand currently at low inventory. | Demand increase for the drug |
30 mg 100 count (NDC 0555-0974-02) | Product Under Allocation | Unprecedented increase in demand being experienced for the product. Supplying at or above demand currently at low inventory. Intermittent supply interruption may be experienced. | Demand increase for the drug |
5 mg 100 count (NDC 0555-0971-02) | Product Under Allocation | Unprecedented increase in demand being experienced for the product. Supplying at or above demand currently at low inventory. | Demand increase for the drug |
USPHARMA WINDLAS (New 03/09/2023)
Presentation | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per FDASIA) |
---|---|---|---|
Amphetamine Mixed Salts Tablets C-II 5 mg, 100 (NDC 72516-016-01) | Unavailable. Estimated recovery: end of June 2023 | Shortage of active ingredient | |
Amphetamine Mixed Salts Tablets C-II 10 mg, 100 (NDC 72516-014-01) | Unavailable. Estimated recovery: end of June 2023 | Shortage of active ingredient | |
Amphetamine Mixed Salts Tablets C-II 15 mg, 100 (NDC 72516-013-01) | Unavailable. Estimated recovery: end of June 2023 | Shortage of active ingredient | |
Amphetamine Mixed Salts Tablets C-II 20 mg, 100 (NDC 72516-012-01) | Unavailable. Estimated recovery: end of June 2023 | Shortage of active ingredient | |
Amphetamine Mixed Salts Tablets C-II 30 mg, 100 (NDC 72516-011-01) | Unavailable. Estimated recovery: end of June 2023 | Shortage of active ingredient |